Sellas Life Sciences Group, Inc. (SLS) fundamentals score
Sellas Life Sciences Group is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Its product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.9 out of 10, Weak long-term fundamentals
- Growth: 2.3/10
- Profitability: not scored
- Financial health: 6.4/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Sellas Life Sciences Group, Inc.’s SEC filings, using the 12 months through 2023-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10